Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Clara Mariette
Observed names:
C Mariette,
C. Mariette
Institutions:
Centre Hospitalier Universitaire de Grenoble,
Hôpital Albert Michallon
Observed institutions:
Centre National de la Recherche Scientifique,
Inserm,
Université Joseph Fourier,
Centre Hospitalier Universitaire de Grenoble,
Translational Innovation in Medicine and Complexity,
Institut pour l'avancée des biosciences,
Hôpital Albert Michallon,
Université Grenoble Alpes
show all 8
OpenAlex ID:
A5049643945
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
2019
·
Paul G Richardson
, Albert Oriol
, et al.
·
The Lancet Oncology
·
421
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
2016
·
Vincent Ribrag
, Serge Koscielny
, et al.
·
The Lancet
·
200
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024
·
Xavier Leleu
, Cyrille Hulin
, et al.
·
Nature Medicine
·
154
PDF
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
2018
·
Nico Gagelmann
, Diderik-Jan Eikema
, et al.
·
Haematologica
·
144
Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
2025
·
Aurore Perrot
, Jérôme Lambert
, et al.
·
New England Journal of Medicine
·
100
Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients
2014
·
R Rahmé
, X Thomas
, et al.
·
Leukemia
·
79
Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus
2013
·
R. Germi
, C. Mariette
, et al.
·
Antiviral Research
·
77
Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia
2014
·
Edouard Cornet
, Cécile Tomowiak
, et al.
·
British Journal of Haematology
·
75
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up
2020
·
Jerome Paillassa
, Edouard Cornet
, et al.
·
Blood Cancer Journal
·
66
PDF
Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study
2016
·
Clara Mariette
, Emmanuelle Tavernier
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
62
Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience
2021
·
Alexis Caulier
, Murielle Roussel
, et al.
·
Blood
·
43
Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
2014
·
X Cahu
, P Chevallier
, et al.
·
Bone Marrow Transplantation
·
43
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
2025
·
Salomon Manier
, Jérôme Lambert
, et al.
·
The Lancet Oncology
·
37
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
2021
·
Jill Corre
, Aurore Perrot
, et al.
·
Leukemia
·
36
PDF
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results
2021
·
Murielle Roussel
, Valerie Lauwers-Cances
, et al.
·
Blood
·
34
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
2024
·
Florent Malard
, Arthur Bobin
, et al.
·
Blood Cancer Journal
·
31
PDF
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
2024
·
Aurore Perrot
, Cyrille Hulin
, et al.
·
Haematologica
·
29
PDF
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
2022
·
Murielle Roussel
, Valérie Lauwers-Cances
, et al.
·
Blood
·
28
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
2018
·
Sophie Park
, Olivier Kosmider
, et al.
·
Haematologica
·
28
PDF
A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a
2025
·
Salomon Manier
, Jerome Lambert
, et al.
·
Blood
·
20
PDF
Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival
2019
·
Julie Mondet
, Caroline Lo Presti
, et al.
·
Haematologica
·
16
PDF
Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)
2021
·
Aurore Perrot
, Valérie Lauwers-Cances
, et al.
·
Blood
·
13
Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression for ruling out myelodysplastic syndromes: a prospective validation study
2021
·
Tatiana Raskovalova
, Marie-Christine Jacob
, et al.
·
Annals of Hematology
·
8
Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial
2016
·
Eileen Mary Boyle
, Marie-Odile Petillon
, et al.
·
Blood
·
7
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study
2024
·
Arthur Bobin
, Salomon Manier
, et al.
·
Haematologica
·
6
PDF
Show more works
View as search
Works count:
63
Citation count:
1,807
H-index:
20
I10-index:
22
Year
Topic
Type